Roka Bioscience, Inc. Demonstrates Utility Of Limits-Based Pathogen Testing For Detection Of Salmonella enterica in Ground Poultry

WARREN, N.J., July 20, 2015 /PRNewswire/ -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced the results of a study demonstrating a limits-based testing application to accurately detect 1 colony forming unit per gram (CFU/g) contamination levels of Salmonella in 375-g ground turkey samples within one working shift. The limits-based testing approach provides an additional tool for monitoring process control and intervening to reduce risk associated with high Salmonella loads entering the marketplace. The limits-based pathogen testing approach for detection of Salmonella enterica in ground poultry will be presented in a poster session at the International Association for Food Protection (IAFP) annual meeting on Sunday, July 26, 2015 in Portland, Oregon.

“The limits-based testing approach is a new application for Roka’s high performing Salmonella detection technology. Our industry partners need innovative tools to help monitor and understand Salmonella loads in the production system in a timely manner. This semi-quantitative tool may be utilized to monitor process control in addition to routine prevalence-based testing procedures,” said W. Evan Chaney, Ph.D., author of the study and Sr. Manager of Scientific Affairs at Roka Bioscience. “The ability to differentiate product with higher initial levels of Salmonella via this limits-based application can help stakeholders make more informed food safety-based decisions.”

In the three-phase study, “Development of a Limits-Based Pathogen Test Application for Detecting Specified Concentrations of Salmonella enterica in Ground Poultry” (abstract P1-56), researchers concluded that the sampling parameters established for the limits-based testing application could detect raw ground turkey product samples with an initial Salmonella load of 1 CFU/g within one production shift.

“Salmonella limits testing approach gave Cargill a tool to measure process control and to manage products posing the greatest risk to public health,” said Melody Thompson MPH, Corporate FSQR Superintendent, Cargill, Inc.

About Roka Bioscience
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our “sample-in, result-out” Atlas System, which automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit http://rokabio.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the “Exchange Act”). These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we “believe”, “expect”, “anticipate”, “plan” and similar expressions) that are not statements of historical fact should be considered forward-looking statements. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the company’s filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update any forward-looking statements, except as may be required by law. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Investor Inquires or Media Related Inquiries
Roka Bioscience, Inc.
ir@rokabio.com
1-855-ROKABIO (855-765-2246)

Logo - http://photos.prnewswire.com/prnh/20150714/236470LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roka-bioscience-demonstrates-utility-of-limits-based-pathogen-testing-for-detection-of-salmonella-enterica-in-ground-poultry-300115810.html

SOURCE Roka Bioscience, Inc.